WCN25-4625 MAXIMISATION OF RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS IN HEART FAILURE PATIENTS WITH CKD USING POTASSIUM BINDER; PRELIMINARY ANALYSIS OF A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

WCN25-4625 MAXIMISATION OF RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS IN HEART FAILURE PATIENTS WITH CKD USING POTASSIUM BINDER; PRELIMINARY ANALYSIS OF A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

Saved in:

Bibliographic Details
Main Authors:	Debasish Banerjee, Irina Chis Ster, Mahrukh Ali, Lisa Anderson, Ella Tumelty, Simran Parmar, Souradip Mookherjee, Daniel Murphy, Tony Lopez, Hilary Warrens
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924033916
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-2370 Effect of initiation and rapid maximisation of RAASi in patients with CKD and heart failure with reduced ejection fraction – observations from the LIFT study, an ongoing trial
by: Mahrukh Ayesha Ali, et al.
Published: (2024-04-01)

Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial
by: Frederik H. Mårup, et al.
Published: (2024-08-01)

The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
by: Eliecer Coto, et al.
Published: (2021-03-01)

Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
by: Laura Bijman, et al.
Published: (2025-04-01)

Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade
by: Nancy Houston Miller
Published: (2010-01-01)

THE GENDER FEATURES OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Advances in the Renin-Angiotensin-Aldosterone System: Relevance to Diabetic Nephropathy
by: Audrey Koitka, et al.
Published: (2008-01-01)

Risk of Hospital Admissions and Death in Patients with Heart Failure and Chronic Kidney Disease: Findings from a Novel Multidisciplinary Clinic
by: Simran Parmar, et al.
Published: (2025-01-01)

Effect of Age on Aldosterone–Renin Ratio in Screening Primary Aldosteronism
by: Ning Peng, et al.
Published: (2025-03-01)

Impaired aldosterone response to potassium and hyperkalemia in patients receiving a renin-angiotensin-aldosterone system inhibitor
by: Miyeon Kim, et al.
Published: (2025-05-01)

Renin‐Angiotensin‐Aldosterone System Profiling in Horses Before and After Exercise
by: Todd Holbrook, et al.
Published: (2025-03-01)

Revisiting the renin-angiotensin-aldosterone system in the eye: Mechanistic insights and pharmacological targets
by: Francesco Buonfiglio, et al.
Published: (2025-06-01)

Age-Related Cutoffs of Plasma Aldosterone/Renin Concentration for Primary Aldosteronism Screening
by: Linqiang Ma, et al.
Published: (2018-01-01)

Role of MicroRNAs in Renin-Angiotensin-Aldosterone System-Mediated Cardiovascular Inflammation and Remodeling
by: Maricica Pacurari, et al.
Published: (2015-01-01)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND REPLICATIVE CELLULAR SENESCENCE: THEIR INTERACTION DURING THE VASCULAR AGEING
by: V. S. Pykhtina, et al.
Published: (2015-09-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Renin-angiotensin-aldosterone system in climacteric women with arterial hypertension. Antihypertensive therapy features
by: A. E. Bragina, et al.
Published: (2005-12-01)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
by: Susan A. S. Farhadi, et al.
Published: (2019-01-01)

The Association between eGFR and the Aldosterone-to-Renin Ratio and Its Effect on Screening for Primary Aldosteronism
by: Jing Xu, et al.
Published: (2020-01-01)

Measurement accuracy and cutoffs for predicting primary aldosteronism diagnosis using Lumipulse® for renin and aldosterone measurements.
by: Maude Laney, et al.
Published: (2025-01-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

Contribution of Four Polymorphisms in Renin-Angiotensin-Aldosterone-Related Genes to Hypertension in a Thai Population
by: Pimphen Charoen, et al.
Published: (2019-01-01)

New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.
by: Miklós Fagyas, et al.
Published: (2014-01-01)

Arterial hypertension in hypothyrosis: severity and state of renin-aldosteron system
by: G. B. Selivanova, et al.
Published: (2004-06-01)

The state of renin-aldosterone system in patients with resistant arterial hypertension
by: О. H. Оbertynska
Published: (2019-06-01)

High Efficiency and Problems of Chemiluminescence Assay-Detected Aldosterone-To-Renin Ratio in Practical Primary Aldosteronism Screening
by: Wenbin Lin, et al.
Published: (2020-01-01)

Upregulation of the Renin-Angiotensin-Aldosterone-Ouabain System in the Brain Is the Core Mechanism in the Genesis of All Types of Hypertension
by: Hakuo Takahashi
Published: (2012-01-01)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM GENES POLYMORPHISM AND RELATION WITH VASOPRESSORS IN ESSENTIAL HYPERTENSION AMONG DAGESTAN INHABITANTS
by: M. Z. Saidov, et al.
Published: (2017-05-01)

Renin Angiotensin Aldosterone System Gene Polymorphisms among Type 2 Diabetic Patients with Retinopathy and Nephropathy
by: Vaishali S. Pawar, et al.
Published: (2024-12-01)

The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Role of renin-angiotensin-aldosterone system gene polymorphisms in the development of diastolic dysfunction in female patients with hypertension
by: Mariya A. Grenaderova, et al.
Published: (2025-01-01)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
by: Davide Stolfo, et al.
Published: (2019-05-01)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
by: Giuseppe MC Rosano, et al.
Published: (2019-11-01)

The outcomes of renin-angiotensin-aldosterone system inhibition and immunosuppressive therapy in children with X-linked Alport syndrome
by: Gülşah Özdemir, et al.
Published: (2023-06-01)

Optimization of renin‐angiotensin‐aldosterone inhibitor therapies for evidence‐based indications: a call to action from the cardio‐kidney community
by: Roberto Pecoits‐Filho, et al.
Published: (2025-08-01)

Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis
by: Ting-Wei Kao, et al.
Published: (2024-12-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Association of the ADRB2 rs1042714 variant with retinopathy of prematurity highlights the importance of the renin-angiotensin-aldosterone system
by: Anna Chmielarz-Czarnocińska, et al.
Published: (2025-04-01)

Place of renin-angiotensin-aldosterone system inhibitors and statins in the treatment of cardiovascular patients in the context of COVID-19 pandemic
by: E. V. Sayutina, et al.
Published: (2022-03-01)

Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system
by: L. M. Resnick, et al.
Published: (2011-12-01)